Volume 6.30 | Aug 7

Mammary Cell News 6.30 August 7, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Target Growth-Driving Cells within Tumors, Not Fastest-Proliferating Cells
To simulate what happens within cancer patients, investigators implanted breast cancer samples in laboratory animals. One set of samples produced tumors that grew very slowly, even though the cells within them were proliferating rapidly, suggesting the tumors were constrained by environmental factors. [Press release from the Dana Farber Cancer Institute discussing online prepublication in Nature] Press Release | Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
PUBLICATIONS (Ranked by impact factor of the journal)

The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy
Researchers report that the transcriptional regulator heat shock factor 1 (HSF1) is frequently activated in cancer-associated fibroblasts, where it is a potent enabler of malignancy. In early-stage breast and lung cancer, high stromal HSF1 activation is strongly associated with poor patient outcome. [Cell]
Abstract | Graphical Abstract | Press Release

​ATM-Mediated Stabilization of ​ZEB1 Promotes DNA Damage Response and Radioresistance through ​CHK1
Epithelial-mesenchymal transition (EMT) is associated with characteristics of breast cancer stem cells, including chemoresistance and radioresistance. Researchers identified an EMT-inducing transcription factor, ​zinc finger E-box binding homeobox 1 (​ZEB1), as a regulator of radiosensitivity and DNA damage response. [Nat Cell Biol] Abstract | Press Release

The Co-Factor of LIM Domains (CLIM/LDB/NLI) Maintains Basal Mammary Epithelial Stem Cells and Promotes Breast Tumorigenesis
The mechanisms of transcriptional regulation of the basal cell compartment are currently unknown. Researchers explored these mechanisms in the basal cell compartment and identified the Co-factor of LIM domains as a transcriptional regulator that maintains these cells. [PLoS Genet] Full Article

A Distinct DNA Methylation Signature Defines Breast Cancer Stem Cells and Predicts Cancer Outcome
Scientists used a whole genome promoter microarray to establish the DNA methylation portraits of breast cancer stem cells (bCSC) and non-bCSCs. [Stem Cells] Abstract

SHON, A Novel Secreted Protein, Regulates Epithelial-Mesenchymal Transition through Transforming Growth Factor (TGF)-β Signaling in Human Breast Cancer Cells
Investigators show that ectopic overexpression of SHON in immortalized human mammary epithelial cells is sufficient for cells to acquire the mesenchymal traits, as well as the enhanced cell migration and invasion, along with the epithelial stem cell properties characterized by increased CD44high/CD24low subpopulation and mammosphere-forming ability. [Int J Cancer] Abstract

MicroRNA-9 Is Associated with Epithelial-Mesenchymal Transition, Breast Cancer Stem Cell Phenotype, and Tumor Progression in Breast Cancer
Investigators evaluated the expression levels of these microRNAs in human breast cancer samples and analyzed their relationship with clinicopathologic features of the tumor including breast cancer subtype, epithelial-mesenchymal transition, breast cancer stem cell phenotype, and prognosis. [Breast Cancer Res Treat] Abstract

Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy via Suppressing Wnt/β-Catenin Signaling Pathway
Researchers investigated the effects of resveratrol on breast cancer stem cells. Resveratrol significantly inhibited the proliferation of breast cancer stem-like cells (BCSCs) isolated from MCF-7 and SUM159, and decreased the percentage of BCSCs population, consequently reducing the size and number of mammospheres in non-adherent spherical clusters. [PLoS One] Full Article

Expression of miR-34c Induces G2/M Cell Cycle Arrest in Breast Cancer Cells
MicroRNA-34 (miR-34) is a family of three miRNAs that have been reported to function as tumor suppressor miRNAs and show decreased expression in various cancers. Scientists examined functions of miR-34c in basal-like breast cancer cells. [BMC Cancer] Full Article


Prognostic Relevance of Disseminated Tumor Cells from the Bone Marrow of Early Stage Breast Cancer Patients – Results from a Large Single-Center Analysis
Investigators determined the prognostic relevance of disseminated tumor cells (DTC) from the bone marrow stage I-III breast cancer patients. They analyzed the impact of DTC detection on adjuvant bisphosphonate treatment efficacy. [Eur J Cancer] Abstract

Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression
The authors describe the modifications of circulating microRNAs (miRNAs) profile after neoadjuvant chemotherapy (NAC) for breast cancer. The expression of 188 circulating miRNAs was assessed in the plasma of 25 patients before and after NAC by RT-qPCR. [J Cell Physiol] Abstract

Read White Paper:  Increase Success Rate Of Compounds In Toxicity Testing
The Mammary Cellular Hierarchy and Breast Cancer
The authors review the discovery, definition and regulation of the mammary cellular hierarchy and describe the development of the concepts that have guided their investigations. They outline recent advances in in vivo lineage tracing that is now challenging many assumptions regarding the behavior of mammary stem cells, and show how understanding these cellular lineages has altered the view of breast cancer. [Cell Mol Life Sci]
Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
UAlbany Biologist Receives $1.43 Million NIH Award for Germline Research to Find Therapies for Cancer and Degenerative Diseases
University at Albany biologist Prashanth Rangan has received a $1.43 million grant from the National Institutes of Health (NIH) for his research into both preventing and inducing differentiation in stem cells in order to treat cancers and degenerative diseases. [University at Albany] Press Release

Funding Awarded for Research into New Wave of Breast Cancer Drugs
Professor Parry Guilford has gained about $200,000 from the Breast Cancer Research Partnership for a two-year project he is leading, titled “Synthetic lethal targeting of lobular breast cancer”. [University of Otago]
Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUOR™ can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW FAST: Functional Analysis & Screening Technologies Congress
November 17-19, 2014
Boston, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast Cancer Metastasis (University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Mammary Stem Cell Biology (University of Amsterdam)

Postdoctoral Fellow – Mammary Differentiation (University of British Columbia)

Postdoctoral Fellow – Molecular Cancer Biology (University of Texas Health Science Center at San Antonio)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us